Payment overview · 2025
General Payments
$816.65
17 reported records · 5 companies
Healthcare provider profile · identity verified
Heath Earl Cotter, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RIFLE, CO · NPI 1184819971
Verified facts
What the public records show
CMS Open Payments records show Heath Earl Cotter, M.D. received $816.65 in general payments during 2025 across 17 reported records.
MIMEDX Group, Inc. accounted for 42.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $347.10 | 42.5% | 9 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $262.93 | 32.2% | 3 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $164.23 | 20.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.79 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.60 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $816.65 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $262.93 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $262.93 | 3 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $164.23 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 75 |
| Losartan Potassium | Losartan Potassium | 289 | 81 |
| Lisinopril | Lisinopril | 248 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 59 |
| Metformin Hcl | Metformin Hcl | 211 | 53 |
| Omeprazole | Omeprazole | 161 | 39 |
| Jardiance | Empagliflozin | 133 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 37 |
| Simvastatin | Simvastatin | 128 | 28 |
| Trazodone Hcl | Trazodone Hcl | 110 | 26 |
| Gabapentin | Gabapentin | 105 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 32 |
| Tramadol Hcl | Tramadol Hcl | 99 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 17 |
| Montelukast Sodium | Montelukast Sodium | 92 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 22 |
| Furosemide | Furosemide | 82 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 20 |
| Mounjaro | Tirzepatide | 80 | suppressed |
| Potassium Chloride | Potassium Chloride | 76 | 22 |
| Trulicity | Dulaglutide | 75 | 12 |
| Allopurinol | Allopurinol | 71 | 20 |
| Carvedilol | Carvedilol | 71 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 26 |
| Ozempic | Semaglutide | 69 | 14 |
| Lamotrigine | Lamotrigine | 63 | suppressed |
| Pregabalin | Pregabalin | 63 | 13 |
| Alendronate Sodium | Alendronate Sodium | 60 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 18 |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 57 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 15 |
| Eliquis | Apixaban | 55 | 13 |
| Meloxicam | Meloxicam | 48 | 11 |
| Sertraline Hcl | Sertraline Hcl | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 22 |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Ezetimibe | Ezetimibe | 39 | 13 |
| Prednisone | Prednisone | 38 | 22 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Famotidine | Famotidine | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Temazepam | Temazepam | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Taltz Autoinjector | Ixekizumab | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Nayzilam | Midazolam | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $816.65 · 17 records | MIMEDX Group, Inc. | CREON, Kerecis GraftGuide, Kerecis SurgiClose, LINZESS, Miro3D, NURTEC ODT, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error